Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent\nPR Newswire\nSAN DIEGO, Feb. 20, 2020\n\n\n\nSAN DIEGO, Feb. 20, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that China has issued Chinese Patent CN106456573B (the \"Patent\") specific to \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy\" to its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTC: KLFE). The Patent strengthens Kannalife's patent portfolio of cannabidiol (CBD)-like molecules. \nKannalife's intellectual property estate of CBD-like molecules (\"KLS Family\"), which is led by KLS-13019, are capable of acting as neuroprotective agents and have the potential to reverse chemotherapy induced neuropathic pain. Under the Patent, Kannalife will further explore the application and potential of its new molecular entities (NMEs) across disease indications marked by neurodegeneration, oxidative stress, and chronic pain. \n\"We're proud of Kannalife's team for the amount of significant progress they've made with KLS-13019 over the past few years,\" said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. \"As the FDA and other national regulatory bodies call for more cannabis and cannabinoid-related research studies in 2020, this new patent furthers Kannalife as a global research leader in the emerging field of cannabinoid therapeutics. We believe that life sciences funds should take notice here as Kannalife is a leading med-chem company in this space.\"\nThe issued Patent is part of the dramatically increasing intellectual propert...